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abstract: Despite the initial reactions of disapproval, more and more fertility clinics are now offering oocyte cryopreservation to
healthy women in order to extend their reproductive options. However, so-called social freezing is not placed on an equal footing with
‘regular’ IVF treatments where public funding is concerned. In those countries or states where IVF patients receive a number of free
cycles, we argue that fertilization and transfer cycles of women who proactively cryopreserved their oocytes should be covered. Moreover,
when the argument of justice is consistently applied, coverage should also include the expenses of ovarian stimulation, oocyte retrieval and
storage. Different modalities are possible: full coverage from the onset, reimbursement in cash or reimbursement in kind, by offering more
free transfer cycles.
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Introduction
The possibility for women to cryopreserve oocytes in order to extend
their reproductive options has gained momentum in recent years. In
the ﬁrst instance, fertility preservation was and is focused on people
whose fertility is endangered by disease (for example Turner syndrome)
or medical treatment (for example radiation or chemotherapy). The
idea that techniques such as oocyte cryopreservation could be
expanded to healthy women to prolong their reproductive lifespan ori-
ginally sparked disapproval and was regarded by many as an unwelcome
development (McCullough, 2004; Jones, 2009). However, as the vitriﬁ-
cation technique moves from an experimental technique to an estab-
lished procedure, arguments to withhold egg freezing from healthy
women become increasingly unconvincing. This is all the more so as
the realization grows that there is often a thin and arbitrary line
between so-calledmedical freezing and so-called elective or social freez-
ing. While acknowledging that the ethical debate on whether social
freezing should be offered in the ﬁrst place, is not yet settled, we will
not reiterate the arguments pro and con as other authors have done
this exercise and quite extensively so (Goold and Savulescu, 2009;
Dondorp and De Wert, 2009; Rybak and Lieman, 2009). Rather, we
start from the observation that fertility clinics in several countries, includ-
ing the USA, the UK, Belgium, The Netherlands and Israel, do not ﬁnd
social freezing immoral and are now catering to women—usually
highly educated, in their late 30s and single (Nekkebroeck et al.,
2010)—who have a strong desire to have children, have few fertile
years ahead of them but are not ready to embark on parenthood just
yet. This evolution has led to another morally contentious question,
namely: who should pay for elective oocyte cryopreservation? ‘Elective
freezing’, ‘non-medical freezing’ or ‘social freezing’ (as opposed to
‘medical freezing’) is currently only available for womenwho are afﬂuent
enough to pay for the ovarian stimulation drugs, medical procedures,
vitriﬁcation or slow freezing procedure and storage fees. Although the
right to reproduce is widely recognized as a liberty-right, it is generally
not regarded as a claim-right (Shanner, 1995). In the context of social
freezing, this means that while women should have the liberty to
cryopreserve their oocytes if they so wish, they cannot make claims
on society to ﬁnancially support their efforts to ward off infertility.
However, many western countries have a healthcare system that
covers a certain number of ‘standard’ IVF cycles to assure equal
access to IVF technology and several US states mandate infertility
insurance coverage. This indicates that, at least in those jurisdictions,
the right to reasonable healthcare is extended to fertility treatment
(ESHRE Task Force on Ethics and Law, 2008).
Should countries with publicly
funded IVF extend coverage to
social freezing?
If oocyte cryopreservation is an accepted procedure to counter infer-
tility and if fertility treatment is covered by public healthcare, should
the logical consequence then be that social freezing is also covered
by public healthcare (or mandated insurance coverage) or is there a
relevant distinction between ‘regular’ IVF and IVF with previously
stored oocytes? The difﬁculty in making this assessment lies in the
fact that elective oocyte freezing consists of two separate steps that
are clearly distinct in time: ﬁrst, ovarian stimulation, oocyte retrieval,
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cryopreservation and storage and second (several years later), thawing
and fertilization of the cryopreserved oocytes. At the time of the ﬁrst
step, women who request social freezing are healthy persons who ask
for a procedure that results in stored oocytes that may or may not be
used, depending on the further course of their lives. At the time of the
second step, they are patients asking for a medical intervention.
A woman presenting at the fertility clinic asking for elective oocyte
cryopreservation thus differs indeed from other IVF patients in a
crucial manner: she is not infertile, which is in most countries a
requirement to receive free IVF cycles. The term ‘elective freezing’
puts the focus on the idea that oocyte cryopreservation by healthy
women resembles other instances of elective medical interventions—
such as cosmetic surgery—that generally have no therapeutic beneﬁt
(unless psychologically). This sparks the sentiment that there is no
reason why society should ﬁnance such ‘whims’ of women who want
to have it all. However, while the line between medical and social inter-
ventions may serve as a general criterion to reimburse or not, there are
many exceptions especially in the ﬁeld of reproduction. Elective abor-
tion, contraception and pregnancy care are prime examples
(Harwood, 2009). Pregnancy is not a disease but we still consider abor-
tion and pregnancy care as medical interventions worthy of reimburse-
ment. Also in the ﬁeld of medically assisted reproduction, numerous
instances (lesbian couples, single women, gamete donation etc.) are
hard to ﬁt in a deﬁnition of ‘medical’. Moreover, social freezing is not a
procedure that is devoid of therapeutic beneﬁts. Although it does not
provide an instant remedy to amedical problem or preventmedical pro-
blems from occurring, it can be described as ‘anticipatory’ medicine:
women anticipate on possible future problems by storing eggs. There
is a possible therapeutic beneﬁt, but instead of being instant, it is
located in the future.
A woman presenting at the fertility clinic, requesting IVF treatment
with her previously stored oocytes, does not differ from other IVF
patients in any crucial manner. For those countries that provide
women who are infertile due to advanced age with a number of free
IVF cycles paid for by the healthcare system, it would seem straightfor-
ward that if these women’s cycles are covered when they use their own
fresh—but old—oocytes or donor oocytes, they should also be covered
when they use their own cryopreserved oocytes. This does not only
follow from the consistency requirement. At the time of use, the
patient’s ownpreviously frozen oocytes have practical and ethical advan-
tages compared with anonymous donor oocytes or the patient’s ‘fresh’
oocytes, and their use should be encouraged. Compared with donor
oocytes, there are no concerns over the welfare of the donor and the
donor-conceived children. Compared with fresh but aged oocytes,
the success rates and health prospects for the resulting babies are
better, as a number of complications in children from (reproductively
speaking) older mothers are related to the age of the oocyte, rather
than to the age of the mother herself. If the two-tiered procedure of
elective cryopreservation and IVF treatment is regarded as a whole,
these arguments lead to the conclusion that it should be reimbursed
according to the same standards as ‘regular’ IVF treatment. However,
as both steps are distinct in time and as step one (storage) does not
necessarily lead to step two (treatment), a more nuanced policy may
be needed. We will consider the option of offering full coverage, but
also the alternative options of offering a refund for the ﬁrst step of the
procedure on the condition that a woman returns for the second
step, either in cash or in kind.
Full coverage
A ﬁrst option would be to cover elective freezing from the onset, merely
setting restrictions on factors such as the number of cycles and the
woman’s age (in light of a reasonable chance of pregnancy), similar to
restrictions for regular IVF. This would lower the threshold for
women to cryopreserve, make the option available to women with
lower incomes and thus increase fair access. However, an implementa-
tion of this strategy would mean that the legal requirement in some
countries of an infertility diagnosis prior to ovarian stimulation cannot
be maintained.
A likely objection to full coverage is that this could be a suboptimal al-
location of scarce funds. Health care budgets are strained and several
countries are already struggling to accommodate the present IVF
demand. At the same time, the added costs might not be
overwhelming. Ovarian stimulation and oocyte retrieval are uncomfort-
able procedures that women will only undertake if they are convinced
that they will actually beneﬁt from the procedure. Moreover, if all
women who have their oocytes frozen would use them later on, there
would actually be a net beneﬁt if one considers the costs per live
birth. The reason behind this is that the live birth rate will be higher
when (frozen-thawed) ‘younger’ eggs are used compared with ‘older’
eggs of subfertile women (Kim et al., 2010), the miscarriage rate will
be lower (Van Loendersloot et al., 2010) and younger oocytes will
lead to fewer chromosomal abnormalities in the offspring. Furthermore,
women opting for social freezing will need fewer stimulation cycles at a
younger age than they will need for regular IVF at an older age and there
will be no need for stimulation of third party donors. ‘Losses’ are only
made when cycles are performed for women who do not return for
treatment and do not donate their oocytes to others. Van Loendersloot
et al. (2011) have calculated that complete coverage is more cost-
effective than the current practice as soon as 61% of women return
for treatment (or donate their oocytes).
A key factor in establishing cost-effectiveness is to attract the cat-
egory of women that is most likely to beneﬁt from the procedure,
meaning those who have a high chance of actually returning for treat-
ment and whose oocytes are frozen at a point when they are still likely
to lead to good fertilization rates. As we argue elsewhere (Mertes and
Pennings, 2011), women who request cryopreservation of their
oocytes between ages 30 and 35 are most likely to meet these criteria.
In light of the lower success rates for ‘older’ women, a policy might be
envisaged that offers full coverage to women younger than, for
example, 36. Currently, most women who want to cryopreserve
their oocytes present themselves too late, namely at an average
reported age of 38 (Gold et al., 2006; Klein et al., 2006; Sage et al.,
2008; Nekkebroeck et al., 2010).
Besides the cost-objection to full coverage, another objection might
be that full coverage would lead to an increase of women opting for
social freezing and to more women postponing motherhood.
Whether the possibility of oocyte cryopreservation will cause a post-
ponement of motherhood is debatable and will only be conﬁrmed or
refuted if and when elective freezing becomes widely available. One
should always keep in mind, however, that when women choose to
store oocytes and postpone motherhood, they do this because in
their eyes, the circumstances for raising a child may or will be better
at a later point in their lives than at the present. Thus, the possibility
that more women will postpone motherhood is not a valid argument
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against public funding, unless one starts from the premise that children
are always better off being born to a young mother than to an older
one, regardless of the circumstances. This is not a plausible premise.
Most women who opt for social freezing postpone motherhood for
lack of a partner (Nekkebroeck et al., 2010). It is not particularly con-
vincing to argue that it is better for these women to become single
mothers at age 35 than sharing parenthood with a partner at age 40.
The fact that more women would be inclined to cryopreserve their
oocytes at a young age can, in contrast, also be regarded as a desirable
evolution in the sense that a greater number of the women who post-
pone motherhood will have young oocytes available to them and thus
fewerwill have to rely on donor oocytes. Another positive consequence
on a societal level is that more donor oocytes will become available for
those women who did not freeze proactively, as there will always be a
certain percentage of women who store their oocytes but eventually
do not return for IVF treatment. Moreover, this new source of donor
oocytes would have fewer ethical objections attached to them, as one
can be sure that the donor voluntarily underwent the ovarian stimulation
and oocyte retrieval procedure. In fact, womenwho have taken the step
to cryopreserve oocytes at one point, but have ultimately decided to
remain childless or whose child wish has been fulﬁlled, have a perfect
donor proﬁle in yet another sense, as they realize how important a
child wish can be, but at the same time no longer have an interest in
using their oocytes themselves. Of course, in countries where donors
are identiﬁable, it is important that women who donate when their
cryostorage ends are warned that they may later be confronted with
their genetic offspring. This, however, also applies to egg sharers and
current oocyte donors.
Partial coverage
Another option is to cover only the second step of the procedure. In
this scenario, the retrieval and storage of oocytes would be paid for by
the woman herself, as she requests an elective procedure without
immediate necessity. Oocyte thawing, fertilization and transfer cycles
would be covered by the same principles of ‘regular’ IVF since the
woman is at that point indiscernible from other IVF patients. The
logic of this scheme is that health insurance only kicks in when a
‘medical’ problem (infertility) presents itself, and at that time the
best treatment option is chosen: either IVF with fresh oocytes from
the patient, IVF with donor oocytes or IVF with previously frozen
oocytes from the patient. If the data on the health of children resulting
from cryopreserved oocytes continue to be reassuring, the latter
option is most likely to be the best option. When cryopreserved
oocytes are already available, the patient does not require ovarian
stimulation, she does not need to rely on donor oocytes and there
is a smaller chance of chromosomal abnormalities in the offspring.
Although this solution is in line with current practice and appears to
be logical, it is not fair toward the women who decide to freeze their
oocytes. In hindsight, a woman who did not cryopreserve eggs at a
younger age will be covered for both steps of the procedure, while
a woman who was more foreseeing and decided to freeze her eggs
beforehand is only covered for the second—and cheapest—step.
Moreover, the former’s procedure is likely to involve more risks for
the resulting children and is less cost-effective.
Cash back
This unfairness could be corrected either by offering women a refund
for the ﬁrst step of their IVF treatment provided that they also
undergo the second step and thus complete the procedure. As
noted by Stoop (2010), ‘it would be illogic not to reimburse these
women when using their vitriﬁed oocytes once they are faced with
infertility while women of the same age get fresh IVF treatments
fully covered’. The refund could either only cover ovarian stimulation
and oocyte retrieval, or also include the costs related to storage.
This cash back-system appears to be the most straightforward and
fair, but there are also some downsides to this approach. As the
moment when a woman ﬁrst pays for the retrieval and storage of
her oocytes and the moment when she would be refunded are
several years apart, the refund of several thousands of Euros/dollars
will be experienced as a considerable ﬁnancial ‘bonus’. Whereas
now, women only turn to IVF after trying to conceive naturally, they
may be tempted to request IVF treatment with their previously cryo-
preserved oocytes (rather than trying to achieve a natural conception)
for reasons of ﬁnancial gain. At ﬁrst sight, this appears to be a case of
‘overuse’ of medical resources. Demanding an infertility diagnosis
before women can undergo covered IVF cycles and claim the refund
is not a guarantee to prevent this. Infertility is not a disease that is
easily diagnosed and often remains unexplained and clinically undetect-
able. The common deﬁnition of infertility is the absence of pregnancy
after a year of regular unprotected intercourse, but it is impossible for
a physician to check this criterion.
Moreover, it is not so clear whether the disadvantage of overuse of
medical resources (in this case replacement cycles) would be justiﬁed
in the given circumstances. Offering (frozen oocyte) replacement
cycles to a 40-year woman whose ovarian reserve is not yet depleted
appears less ethically challenging than pushing her to reproduce natur-
ally with higher chances of miscarriage and chromosomal abnormal-
ities in the resulting child while she has ‘young’ oocytes in storage.
More free transfer cycles
A ﬁnal strategy might be not to offer a refund in cash for women who
request IVF treatment with previously frozen oocytes, but to offer
them a refund in kind, more speciﬁcally a number of additional transfer
cycles. The cost of thawing, fertilization and transfer of the embryo is
considerably lower than the cost of a full IVF cycle and thus many
more replacement cycles can be offered for the same price. In this
kind of arrangement, women are not ﬁnancially motivated to
undergo IVF while they are still fertile. A practical disadvantage of
this scheme is that coverage is generally calculated per stimulation
cycle, not per transfer cycle. One would need to compare the total
cost of an IVF cycle (which usually includes several replacement
cycles for fresh and thawed oocytes or embryos) to the cost of
thawing, fertilization and replacement in order to determine how
many transfer cycles would equal the price of an average full IVF cycle.
In countries that already cover several IVF cycles, this arrangement
loses a lot of its appeal as women who opt for elective freezing are
unlikely to need these ‘extra’ transfer cycles. Still, although there is
no perfect equality of both groups (IVF patients of advanced age
with or without previously cryopreserved oocytes), there is at least
an attempt to limit the inequality.
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Which strategy is most sound?
Of the four strategies that we discussed, the one that presents the
biggest challenge to the values of justice and equality is partial
funding, which is in fact common practice at present. From the pro-
posed alternatives, the cash back-system is expected to be the
most appealing one as it is cost-effective, no public money is
‘wasted’ on unnecessary medical procedures, it is compatible with
the widespread legal requirement that IVF cycles are only
covered when there is a diagnose of infertility and it is fair when
comparing women faced with age-related infertility who did previ-
ously cryopreserve their oocytes to those who did not. However,
it is not a fair system when one compares women who freeze
and return for treatment to those who do not return. We might
imagine two single women who freeze their eggs at the age of
34, hoping to ﬁnd a suitable partner soon, rather than having to
decide to have children either alone or with an unsuitable
partner. One ﬁnds a partner to share parenthood with and
returns for treatment at the age of 38, while the other remains
single, does not want to be a single mother and therefore does
not return for treatment. Only the ﬁrst woman will be reimbursed,
although there is no morally relevant reason that sets her apart
from the second, other than that she was more lucky. As such,
the second woman actually suffers a ‘double loss’.
Whether the fourth strategy (extra transfer cycles) offers an
actual advantage or not will depend largely on the local context.
In Belgium, for example, six IVF cycles are covered by public
health insurance. Taking into consideration that each of these six
started cycles represents several transfer cycles, it is very unlikely
that patients would beneﬁt from extra cycles. In places where
only one or two cycles are free of charge, however, extra free re-
placement cycles will often be useful.
Also, the appeal of the ﬁrst strategy—full coverage—will depend on
local factors. While it is a fair system that would improve success rates
for women treated for age-onset infertility, the public healthcare
system probably will not want to add women who request social
freezing to the waiting lists of women who are already subfertile and
who are sure to want IVF treatment. In countries where there are
no waiting lists, however, full coverage up to a certain age might act
as an incentive for women to freeze their eggs at a time when they
are still sufﬁciently fertile, rather than at a time when they become
desperate.
On a policy level, a systematic analysis of these local legal and con-
textual factors should be undertaken in order to determine which
strategy is the most ‘fair’ for all parties involved, given the local
context. Even a combination of several policies might be envisaged.
For example, for a country such as Belgium, we could imagine a
system in which women who cryopreserve their oocytes before the
age of 36 are covered in full, while women who cryopreserve their
oocytes at a higher age would only be covered for fertilization and
transfer. Such a policy may be justiﬁed based on a trade-off
between considerations regarding equity of access, cost-effectiveness
and public education (namely: that oocyte freezing is best done
before the age of 36). In the UK, in contrast, a system that offers
more free transfer cycles might be the better choice when there are
already many infertile couples on the waiting lists.
Conclusion
Although elective oocyte cryopreservation—better known as social
egg freezing—is being offered by an increasing number of fertility
clinics, it is far from clear what its place is—or should be—within
systems that offer a number of free IVF cycles. If women who have
proactively cryopreserved their oocytes return for treatment at a
point when they can no longer conceive naturally and have not
reached the maximum age limit for embryo transfer, they should be
treated on equal terms with other IVF patients and also receive free
treatment. It is less straightforward, however, whether or not the
covered cycles should include the ﬁrst step of the procedure,
namely the costs related to ovarian stimulation, oocyte retrieval,
oocyte freezing (vitriﬁcation) and storage. Although paying for elective
procedures is counterintuitive, there are good reasons to argue for full
coverage from the onset. Alternatively, a cash back-system or more
free transfer cycles could be considered. The preferred strategy will
often depend on local legal and contextual factors.
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